oasis-4 semaglutide Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) (oral semaglutide/Wegovy, 64 weeks). For educational comparison only—these are Novo Nordisk's Phase III OASIS

Wegovy Dosing Schedule Month 1 (Weeks 1-4): 0.25 mg weekly Month 2 (Weeks 5-8): 0.5 mg weekly Month 3 (Weeks 9-12): 1 mg weekly Month 4 (Weeks 13-16): 1.7 mg weekly Month 5+ (Week 17+): 2.4 mg weekly (maintenance dose) Youll reach the maximum dose after about 16-20 weeks

The FDA has recently announced a significant change in the availability of compounded tirzepatide, a medication known for its benefits in treating type 2 diabetes and supporting weight loss efforts

[1] Wegovy single-dose pens may be kept at room temperature (up to 86F) for up to 28 days before use

Regular check-ups and blood tests can help monitor these conditions, allowing for timely interventions that can support your overall health and weight management goals